- BSD Medical (BSDM -2.7%) initiates a 28-patient Phase 1/2 clinical trial evaluating the use of hyperthermia combined with proton radiotherapy as a treatment for patients with unresectable soft tissue sarcoma. Investigators will use the company's BSD-2000 System or BSD-500 System to deliver the hyperthermia. The systems deliver localized therapeutic heating by applying radiofrequency (RF) energy.